Portal de Periódicos da CAPES

Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials

2021; Springer Science+Business Media; Volume: 47; Issue: 6 Linguagem: Inglês

10.1007/s00134-021-06416-z

1432-1238

Timothy Arthur Chandos Snow, Naveed Saleem, Gareth Ambler, Eleni Nastouli, Mervyn Singer, Nishkantha Arulkumaran,

SARS-CoV-2 and COVID-19 Research

Interleukin-6 (IL-6) levels discriminate between patients with mild and severe COVID-19, making IL-6 inhibition an attractive therapeutic strategy. We conducted a systematic review, meta-analysis, trial sequential analysis (TSA), and meta-regression of randomized-controlled trials to ascertain the benefit of IL-6 blockade with tocilizumab for COVID-19.